Inventor · disambiguated record
Yun Oliver Long
Also filed as: LONG YUN · LONG YUN OLIVER
35 granted patents·5 pending applications·538 citations·filing 2004–2024
98Inventor score
Top patents by PatentIndex Score
40 records- 0198US10144724B2Substituted quinazoline compounds and methods of use thereofARAXES PHARMA LLC·Filed 2016·Granted Dec 4, 2018·44 cites·42 claims
- 0297US10370386B2Substituted quinolines as inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2017·Granted Aug 6, 2019·33 cites·30 claims
- 0397US10351550B2Substituted quinazoline compounds and methods of use thereofARAXES PHARMA LLC·Filed 2018·Granted Jul 16, 2019·27 cites·32 claims
- 0497US10246424B2Substituted quinazoline compounds and methods of use thereofARAXES PHARMA LLC·Filed 2016·Granted Apr 2, 2019·36 cites·90 claims
- 0597US9988357B2Methods for preparation of quinazoline derivativesARAXES PHARMA LLC·Filed 2016·Granted Jun 5, 2018·38 cites·32 claims
- 0697US9840516B2Substituted quinazolines as inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2014·Granted Dec 12, 2017·73 cites·33 claims
- 0796US10927125B2Substituted cinnolines as inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2019·Granted Feb 23, 2021·11 cites·29 claims
- 0896US10858343B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted Dec 8, 2020·11 cites·15 claims
- 0996US10829458B2Substituted quinazoline compounds and methods of use thereofARAXES PHARMA LLC·Filed 2019·Granted Nov 10, 2020·13 cites·29 claims
- 1096US10730867B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted Aug 4, 2020·15 cites·19 claims
- 1196US10723738B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2019·Granted Jul 28, 2020·15 cites·22 claims
- 1296US10689356B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted Jun 23, 2020·16 cites·15 claims
- 1396US10414757B22-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereofARAXES PHARMA LLC·Filed 2016·Granted Sep 17, 2019·33 cites·49 claims
- 1496US10280172B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2017·Granted May 7, 2019·34 cites·19 claims
- 1595US10428064B2Fused-tricyclic inhibitors of KRAS and methods of use thereofARAXES PHARMA LLC·Filed 2016·Granted Oct 1, 2019·27 cites·28 claims
- 1695US10011600B2Methods and compositions for inhibition of RasARAXES PHARMA LLC·Filed 2015·Granted Jul 3, 2018·12 cites·21 claims
- 1794US11878985B2Substituted quinazolines as inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2020·Granted Jan 23, 2024·2 cites·43 claims
- 1894US11021470B22-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereofARAXES PHARMA LLC·Filed 2019·Granted Jun 1, 2021·8 cites·21 claims
- 1994US10882847B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted Jan 5, 2021·11 cites·23 claims
- 2094US10875842B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted Dec 29, 2020·11 cites·20 claims
- 2193US10975071B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted Apr 13, 2021·9 cites·20 claims
- 2293US10647703B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted May 12, 2020·18 cites·13 claims
- 2390US10683304B2Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancerCAPELLA THERAPEUTICS INC·Filed 2019·Granted Jun 16, 2020·5 cites·30 claims
- 2488US10647707B2Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancerCAPELLA THERAPEUTICS INC·Filed 2018·Granted May 12, 2020·4 cites·41 claims
- 2588US10005765B2Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancerCAPELLA THERAPEUTICS INC·Filed 2015·Granted Jun 26, 2018·8 cites·50 claims
- 2688US2024352028A1Substituted quinazolines as inhibitors of kras g12cARAXES PHARMA LLC·Filed 2024·Application pending·0 cites
- 2786US10202398B2Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancerCAPELLA THERAPEUTICS INC·Filed 2015·Granted Feb 12, 2019·6 cites·20 claims
- 2884US2024043441A1Inhibitors of kras g12cARAXES PHARMA LLC·Filed 2023·Application pending·0 cites
- 2984US2023303586A1Inhibitors of kras g12cARAXES PHARMA LLC·Filed 2023·Application pending·0 cites
- 3083US11242352B2Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancerCAPELLA THERAPEUTICS INC·Filed 2020·Granted Feb 8, 2022·1 cites·20 claims
- 3182US2025092028A1Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancerCAPELLA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3281US12234244B2Substituted piperazines as inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2022·Granted Feb 25, 2025·0 cites·12 claims
- 3380USRE50490ESubstituted quinazoline compounds and methods of use thereofARAXES PHARMA LLC·Filed 2022·Granted Jul 15, 2025·0 cites·29 claims
- 3480US11427565B2Benzimidazoles for use in the treatment of cancer and inflammatory diseasesCAPELLA THERAPEUTICS INC·Filed 2020·Granted Aug 30, 2022·1 cites·21 claims
- 3578US7816372B26-cycloamino-2-quinolinone derivatives as androgen receptor modulator compoundsLIGAND PHARM INC·Filed 2004·Granted Oct 19, 2010·11 cites·42 claims
- 3677US10590108B2Benzimidazoles for use in the treatment of cancer and inflammatory diseasesCAPELLA THERAPEUTICS INC·Filed 2016·Granted Mar 17, 2020·2 cites·22 claims
- 3773US11713322B2Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancerCAPELLA THERAPEUTICS INC·Filed 2021·Granted Aug 1, 2023·0 cites·21 claims
- 3871US2023271938A1Benzimidazoles for use in the treatment of cancer and inflammatory diseasesCAPELLA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3969US9440957B2Compounds and compositions for modulating EGFR ActivityLELAIS GERALD·Filed 2013·Granted Sep 13, 2016·3 cites·21 claims
- 4066US11787788B2Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereofCAPELLA THERAPEUTICS INC·Filed 2020·Granted Oct 17, 2023·0 cites·23 claims
Join the waitlist — get patent alerts
Get an alert when Yun Oliver Long files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →